Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 7 pages · English
• Cash and cash equivalents at the end of the quarter increased by $0.224 million to $0.946 million. Melbourne, Australia; 29 January 2026: Specialty topical pharmaceuticals company Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to report an increase in Cash and cash equivalents to $0.946 million from $0.722 million for the three months ended 31 December 2025 and to provide a busines
Story so far
Earlier from Acrux
- Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream
- AGM Presentation and Address
- Acrux receives $0.4m advance on FY26 R&D Tax Incentive
- Received $3.04m RDTI rebate for FY25
- Appendix 4E and Full Year Statutory Accounts FY25
Later from Acrux
- Half Yearly Report and Accounts
- Acrux receives $0.55m advance on FY26 R&D Tax Incentive
- Acrux strategy focuses on Female Testosterone for low libido
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
- Acrux raises $1.6 million via Share Placement
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux